Mwandishi:
Mhariri:
Imeboreshwa;
ULY CLINIC
ULY CLINIC
15 Julai 2026, 01:53:45
Megaloblastic Anemia
Megaloblastic anemia is a macrocytic anemia characterized by ineffective erythropoiesis and the presence of large, structurally abnormal, immature red blood cell precursors (megaloblasts) in the bone marrow.
It is most commonly caused by:
Vitamin B12 (cobalamin) deficiency
Folate (vitamin B9) deficiency
Both vitamins are essential for DNA synthesis, and their deficiency results in defective nuclear maturation with preserved cytoplasmic development (nuclear–cytoplasmic asynchrony).
Pathophysiology
Impaired thymidine synthesis → defective DNA replication
Delayed nuclear maturation
Ineffective hematopoiesis
Intramedullary hemolysis
Pancytopenia (in severe cases)
Vitamin B12 deficiency uniquely affects the nervous system, leading to demyelination (subacute combined degeneration).
Risk Factors
Vitamin B12 Deficiency
Pernicious anemia (autoimmune intrinsic factor deficiency)
Gastrectomy or bariatric surgery
Chronic gastritis
Malabsorption (Crohn’s disease, celiac disease)
Long-term metformin use
Strict vegan diet
Elderly age
Fish tapeworm (Diphyllobothrium latum)
Folate Deficiency
Poor dietary intake
Chronic alcoholism
Pregnancy
Hemolytic anemia (increased demand)
Malabsorption
Methotrexate or anticonvulsant therapy
Signs and Symptoms
General Anemia Features
Pallor
Fatigue
Dyspnea
Tachycardia
Characteristic Features
Mild jaundice (lemon-yellow tint)
Glossitis (beefy red tongue)
Hyperpigmentation of palms
Hair loss
Depression
Weight loss
Neurological Features (Vitamin B12 Deficiency)
Paresthesia (pins and needles)
Numbness (hands and feet)
Ataxic gait
Loss of vibration and position sense
Tremors
Peripheral neuropathy
Cognitive changes
Psychosis (rare)
Neurological symptoms may occur even without severe anemia.
Diagnostic Criteria
Diagnosis is based on:
Macrocytic anemia
Laboratory evidence of B12 or folate deficiency
Characteristic peripheral smear findings
Clinical features
Investigations
Perform the following investigations as appropriate:
Full blood count (FBC):
Low haemoglobin
Raised mean corpuscular volume (MCV)
Pancytopenia may be present
MCV may be normal or low if iron deficiency coexists (combined deficiency anaemia)
Peripheral blood smear
Serum vitamin B12 level
Serum folate level
Thyroid-stimulating hormone (TSH)
Reticulocyte count
Bone marrow aspiration, when indicated
Differential Diagnosis
Liver disease
Hypothyroidism
Alcoholism
Myelodysplastic syndrome
Aplastic anemia
Drug-induced macrocytosis
Treatment
Treatment depends on the underlying deficiency.
Non-Pharmacological Management
Dietary counseling
Alcohol cessation
Management of malabsorption
Treat underlying gastrointestinal pathology
Pharmacological management
Management depends on the underlying cause and the presence or absence of neurological involvement.
Vitamin B12 deficiency without neurological involvement
Hydroxocobalamin (IM)
1 mg three times weekly for 2 weeks.
Then 1 mg every 3 months.
Monitoring
Review blood counts and perform clinical assessment every 3 months.
Pernicious anaemia (vitamin B12 deficiency with neurological involvement)
Hydroxocobalamin (IM)
1 mg on alternate days until there is no further neurological improvement (maximum reversal of neurological or neuropsychiatric signs and symptoms).
Then 1 mg every 2–3 months.
AND
Folic acid (PO)
5 mg once daily for at least 3 months.
Important: Folic acid must be started simultaneously with vitamin B12 therapy.
AND
Ferrous sulphate (PO)
200 mg every 8 hours for at least 3 months.
Monitoring Response
Reticulocyte rise within 5–7 days
Hemoglobin improves within 2–3 weeks
Full correction in ~2 months
Neurological recovery may take months
Complications
Irreversible neuropathy (untreated B12 deficiency)
Cognitive impairment
Subacute combined degeneration
Heart failure (severe anemia)
Infertility
Increased thrombotic risk (elevated homocysteine)
Prevention
Balanced diet rich in:
Meat, fish, dairy (B12)
Leafy greens (folate)
Supplementation in:
Pregnancy
Chronic hemolytic anemia
Malabsorption syndromes
Lifelong B12 in pernicious anemia
Screening high-risk elderly patients
Prognosis
Excellent with early treatment
Neurological complications reversible if treated promptly
Pernicious anemia requires lifelong therapy
Imeandikwa:
14 Novemba 2020, 13:56:36
Rejea za mada:
1. STG
